Cargando…
A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer
This study investigated the maximum-tolerated dose of gemcitabine based on the frequency of dose-limiting toxicities of weekly gemcitabine treatment with concurrent radiotherapy in patients with locally advanced pancreatic cancer. Fifteen patients with locally advanced pancreatic cancer that was his...
Autores principales: | Ikeda, M, Okada, S, Tokuuye, K, Ueno, H, Okusaka, T |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746589/ https://www.ncbi.nlm.nih.gov/pubmed/12085203 http://dx.doi.org/10.1038/sj.bjc.6600256 |
Ejemplares similares
-
Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer
por: Okusaka, T, et al.
Publicado: (2004) -
A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer
por: Ikeda, M, et al.
Publicado: (2007) -
Weekly full-dose gemcitabine and single-dose cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer
por: Hong, S P, et al.
Publicado: (2008) -
Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer
por: Ma, Yang-Yang, et al.
Publicado: (2020) -
A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer
por: Michael, M, et al.
Publicado: (2009)